miRagen Expands Senior Leadership Team
Adam Levy Joins as Chief Business Officer
BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics, today announced the appointment of Adam Levy to the position of Chief Business Officer. Concurrent with Mr. Levy’s appointment, Christopher J. Morl has been appointed to the position of Chief Operating Officer.
“We view Mr. Levy’s investment banking and transaction experience as a valuable addition to our senior management team,” said William S. Marshall, Ph.D., President and Chief Executive Officer. “During the past year miRagen has initiated first-in-human clinical trials for two product candidates, MRG-106 and MRG-201, and the appointments of Mr. Levy and Mr. Morl enhance our capabilities to progress our corporate and financing goals as a clinical-stage company.”
Mr. Levy brings over 16 years of advisory experience primarily in the life sciences sector to miRagen. Prior to joining miRagen, he was a Senior Vice President at Wedbush Securities where he served since 2013 in the healthcare investment banking group. Mr. Levy has expertise in corporate strategy, M&A and partnering with experience in completing more than $30 billion in financing and advisory transactions. Prior to joining Wedbush, he held positions of increasing responsibility in investment banking at Merrill Lynch and Jefferies. Mr. Levy earned a B.S. in Applied Economics from Cornell University.
“With two novel programs in the clinic and a focus on diseases with high unmet medical need, I believe miRagen is poised to make a difference in the lives of patients,” said Mr. Levy. “I am excited to join this talented team and contribute to the success of miRagen Therapeutics as we develop our pipeline of product candidates across multiple disease areas.”
About microRNAs
MicroRNAs have emerged as an important class of small RNAs encoded in the genome, acting as master regulators of gene expression. Recent studies have indicated that microRNAs appear to be associated with many disease processes. Because they are thought to be single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes.
About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need. The Company seeks to leverage in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance promising technologies and high-potential product candidates for its own pipeline and in conjunction with strategic collaborators. For certain cardiovascular disease programs, miRagen has a collaboration and license agreement with Servier, an independent French research-based pharmaceutical company. miRagen retains all rights for the Servier-partnered programs in the U.S. and Japan.
For more information, please visit www.miragenrx.com.
For information on clinical trials please visit www.clinicaltrials.gov.
Safe Harbor Statement
This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the role of microRNAs in disease processes and as potential drug products, the potential for MRG-106, MRG-107 and MRG-201 to target diseases, the adequacy of the Company’s capital to support its future operations and the Company’s ability to successfully initiate and complete clinical trials. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; and, the impact of competitive products and technological changes. The Company disclaims any intent or obligation to update these forward-looking statements.
Contacts
miRagen Therapeutics, Inc.
Christopher J. Morl, 720-407-4598
Chief Operating Officer
cmorl@miragenrx.com
“We view Mr. Levy’s investment banking and transaction experience as a valuable addition to our senior management team,” said William S. Marshall, Ph.D., President and Chief Executive Officer. “During the past year miRagen has initiated first-in-human clinical trials for two product candidates, MRG-106 and MRG-201, and the appointments of Mr. Levy and Mr. Morl enhance our capabilities to progress our corporate and financing goals as a clinical-stage company.”
Mr. Levy brings over 16 years of advisory experience primarily in the life sciences sector to miRagen. Prior to joining miRagen, he was a Senior Vice President at Wedbush Securities where he served since 2013 in the healthcare investment banking group. Mr. Levy has expertise in corporate strategy, M&A and partnering with experience in completing more than $30 billion in financing and advisory transactions. Prior to joining Wedbush, he held positions of increasing responsibility in investment banking at Merrill Lynch and Jefferies. Mr. Levy earned a B.S. in Applied Economics from Cornell University.
“With two novel programs in the clinic and a focus on diseases with high unmet medical need, I believe miRagen is poised to make a difference in the lives of patients,” said Mr. Levy. “I am excited to join this talented team and contribute to the success of miRagen Therapeutics as we develop our pipeline of product candidates across multiple disease areas.”
About microRNAs
MicroRNAs have emerged as an important class of small RNAs encoded in the genome, acting as master regulators of gene expression. Recent studies have indicated that microRNAs appear to be associated with many disease processes. Because they are thought to be single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes.
About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need. The Company seeks to leverage in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance promising technologies and high-potential product candidates for its own pipeline and in conjunction with strategic collaborators. For certain cardiovascular disease programs, miRagen has a collaboration and license agreement with Servier, an independent French research-based pharmaceutical company. miRagen retains all rights for the Servier-partnered programs in the U.S. and Japan.
For more information, please visit www.miragenrx.com.
For information on clinical trials please visit www.clinicaltrials.gov.
Safe Harbor Statement
This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the role of microRNAs in disease processes and as potential drug products, the potential for MRG-106, MRG-107 and MRG-201 to target diseases, the adequacy of the Company’s capital to support its future operations and the Company’s ability to successfully initiate and complete clinical trials. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; and, the impact of competitive products and technological changes. The Company disclaims any intent or obligation to update these forward-looking statements.
Contacts
miRagen Therapeutics, Inc.
Christopher J. Morl, 720-407-4598
Chief Operating Officer
cmorl@miragenrx.com